In today’s healthcare landscape, medical practices work hard to deliver excellent patient care while also ensuring smooth financial operations. But even the most well-run practices can fall into ...
MELBOURNE, Australia, July 9, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that its next-generation PSMA [1] PET [2] imaging agent, Gozellix® ...
HCPCS code Q1003 (New technology intraocular lens category 3 (reduced spherical aberration)) will no longer be reportable under the ASC payment system. ASCs were instructed to report HCPCS code Q1003 ...
DENVER, March 26, 2025--(BUSINESS WIRE)--TriSalus Life Sciences®, Inc. ("TriSalus" or the "Company") (Nasdaq: TLSI), which seeks to transform outcomes for patients with solid tumors by integrating our ...
DENVER--(BUSINESS WIRE)--TriSalus Life Sciences® Inc., (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver ...
, (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, is pleased to announce today ...
Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that a specific Healthcare Common Procedure Coding System (HCPCS) ...
This biotech could be high risk, high reward picks according to Bell Potter. The post Why Mesoblast shares could rise 40% in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback